MX2019004484A - Derivados de naftiridinona y su uso en el tratamiento de la arritmia. - Google Patents

Derivados de naftiridinona y su uso en el tratamiento de la arritmia.

Info

Publication number
MX2019004484A
MX2019004484A MX2019004484A MX2019004484A MX2019004484A MX 2019004484 A MX2019004484 A MX 2019004484A MX 2019004484 A MX2019004484 A MX 2019004484A MX 2019004484 A MX2019004484 A MX 2019004484A MX 2019004484 A MX2019004484 A MX 2019004484A
Authority
MX
Mexico
Prior art keywords
arrhythmia
treatment
naphthyridinone derivatives
present
naphthyridinone
Prior art date
Application number
MX2019004484A
Other languages
English (en)
Inventor
Peukert Stefan
Yamada Ken
Thomas Parker David
Liao Lv
Yasoshima Kayo
Barbe Guillaume
Raymond Bebernitz Gregory
Geng Sicong
Belgin Gulgeze Efthymiou Hatice
Ma Fupeng
Mo Ruowei
Peng Yunshan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019004484A publication Critical patent/MX2019004484A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo; (I) donde R1, R3-R6, X2 y X3 son como se define en la presente descripción, un método para elaborar los compuestos de la invención, y sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica. (ver Fórmula).
MX2019004484A 2016-10-21 2017-10-19 Derivados de naftiridinona y su uso en el tratamiento de la arritmia. MX2019004484A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662410930P 2016-10-21 2016-10-21
CN2016102928 2016-10-21
US201662413292P 2016-10-26 2016-10-26
PCT/IB2017/056515 WO2018073788A1 (en) 2016-10-21 2017-10-19 Naphthyridinone derivatives and their use in the treatment of arrhythmia

Publications (1)

Publication Number Publication Date
MX2019004484A true MX2019004484A (es) 2019-08-05

Family

ID=60409317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004484A MX2019004484A (es) 2016-10-21 2017-10-19 Derivados de naftiridinona y su uso en el tratamiento de la arritmia.

Country Status (33)

Country Link
US (3) US10266531B2 (es)
EP (2) EP3529251B1 (es)
JP (1) JP7030802B2 (es)
KR (1) KR102540872B1 (es)
CN (1) CN109843887B (es)
AU (2) AU2017344489C1 (es)
BR (1) BR112019007863A2 (es)
CA (1) CA3038624A1 (es)
CL (1) CL2019001023A1 (es)
CO (1) CO2019003894A2 (es)
CR (1) CR20190201A (es)
CU (1) CU24599B1 (es)
DO (1) DOP2019000100A (es)
EC (1) ECSP19026973A (es)
ES (1) ES2934234T3 (es)
FI (1) FI3529251T3 (es)
HR (1) HRP20221516T1 (es)
HU (1) HUE060882T2 (es)
IL (1) IL266128B (es)
JO (1) JOP20190086A1 (es)
LT (1) LT3529251T (es)
MX (1) MX2019004484A (es)
PE (1) PE20190735A1 (es)
PH (1) PH12019500849A1 (es)
PL (1) PL3529251T3 (es)
PT (1) PT3529251T (es)
RS (1) RS63841B1 (es)
SA (1) SA519401614B1 (es)
SG (1) SG11201902529WA (es)
SI (1) SI3529251T1 (es)
TW (1) TWI759343B (es)
UY (1) UY37445A (es)
WO (1) WO2018073788A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EP3814347B1 (en) * 2018-06-27 2023-05-03 Bristol-Myers Squibb Company Naphthyridinone compounds useful as t cell activators
WO2022074567A1 (en) * 2020-10-06 2022-04-14 Novartis Ag Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia
AR127698A1 (es) * 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022214A (en) 1963-01-31 1966-03-09 Sterling Drug Inc Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
IL51092A0 (en) 1976-12-10 1977-02-28 Abic Ltd Naphthyridine derivatives and their preparation
JPS57176959A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd 1-(2',6'-dichlorophenyl)-2,3bis(methylthio) indole and its preparation
JPS57176958A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd 1-(2',6'-dichlorophenyl)-2-methylthioindole and its preparation
JPS57176956A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone
JPS57176957A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
FI77669C (fi) 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4698341A (en) 1983-07-30 1987-10-06 Godecke Aktiengesellschaft Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
EP0512042B1 (en) 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
EP0787720B1 (en) 1994-10-20 2003-07-16 Wakunaga Seiyaku Kabushiki Kaisha Pyridonecarboxylate derivative or salt thereof and antibacterial containing the same as active ingredient
US6211375B1 (en) 1996-04-19 2001-04-03 Wakunaga Pharmaceutical Co., Ltd. Pyridonecarboxylic acid derivatives or salts thereof and antibacterial agents containing the same as the active ingredient
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
JP3448305B2 (ja) 1996-11-28 2003-09-22 湧永製薬株式会社 新規ピリドンカルボン酸誘導体又はその塩及びこれを有効成分とする医薬
JP2002517486A (ja) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
WO2000007595A1 (en) 1998-08-03 2000-02-17 Basf Corporation Pyridinones for the treatment of sexual dysfunction
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6683113B2 (en) 1999-09-23 2004-01-27 Pharmacia Corporation (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
WO2001076574A2 (en) 2000-04-12 2001-10-18 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
JP2003040866A (ja) 2001-07-31 2003-02-13 Nippon Kayaku Co Ltd Ｎ置換インドール誘導体、その製造法及びそれを有効成分とする害虫防除剤
RU2004112771A (ru) 2001-09-26 2005-10-10 Байер Фармасьютикалс Корпорейшн (US) Производные 1, 8-нафтиридина как противодиабетические средства
US20040248956A1 (en) 2002-01-29 2004-12-09 Hagmann William K Substituted imidazoles as cannabinoid receptor modulators
AU2003273192A1 (en) 2002-05-31 2003-12-19 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and diabetes-related disorders
CN100404535C (zh) 2002-08-07 2008-07-23 诺瓦提斯公司 用作治疗醛固酮介导的病症的药物的有机化合物
EP1565463B1 (en) 2002-11-18 2008-06-11 Novartis AG Imidazo[1,5a] pyridine derivatives and methods for treating aldosterone mediated diseases
US20060194782A1 (en) 2003-09-18 2006-08-31 Altana Pharma Ag Pharmacologically active imidazo[4,5-c] pyridines
ATE549024T1 (de) 2003-09-23 2012-03-15 Merck Sharp & Dohme Chinazolin-kaliumkanalhemmer
PT1732933E (pt) 2004-03-26 2008-10-20 Lilly Co Eli Compostos para o tratamento da dislipidémia
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
DE102004018198A1 (de) 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
US20080076794A1 (en) 2004-05-28 2008-03-27 Peter Herold Heterocyclic Compounds And Their Use As Aldosterone Synthase Inhibitors
TW200612947A (en) 2004-05-28 2006-05-01 Speedel Experimenta Ag Organic compounds
CN1997643A (zh) 2004-05-28 2007-07-11 斯皮德尔实验股份公司 杂环化合物及其作为醛固酮合酶抑制剂的应用
PL1773816T3 (pl) 2004-06-24 2015-06-30 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
WO2006005726A2 (en) 2004-07-09 2006-01-19 Speedel Experimenta Ag Heterocyclic compounds
DE102004054215A1 (de) 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
ES2525217T3 (es) 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP1783114A1 (en) 2005-11-03 2007-05-09 Novartis AG N-(hetero)aryl indole derivatives as pesticides
AU2006318212C1 (en) 2005-11-23 2012-08-30 The Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
AR056888A1 (es) 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
EP2009080A4 (en) 2006-04-04 2010-05-26 Taiyo Nippon Sanso Corp PROCESS FOR SEPARATION OF METHANE, METHANE SEPARATOR AND METHANE USE SYSTEM
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
EP2057163A1 (en) 2006-08-25 2009-05-13 Novartis AG Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
WO2008076336A2 (en) 2006-12-18 2008-06-26 Novartis Ag Imidazoles as aldosterone synthase inhibitors
EP2121652A1 (en) 2006-12-18 2009-11-25 Novartis AG 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
BRPI0721290A2 (pt) 2006-12-18 2014-03-25 Novartis Ag Compostos orgânicos
TW200904416A (en) 2007-03-29 2009-02-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US8338406B2 (en) 2008-02-22 2012-12-25 Otsuka Pharmaceutical Co., Ltd. Benzodiazepine compound and pharmaceutical composition
WO2010012745A2 (en) 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh Benzimidazoles
CA2770626A1 (en) 2009-08-10 2011-02-17 Mark Smith Functionalisation of solid substrates
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
KR101477156B1 (ko) 2010-08-25 2014-12-29 (주)네오팜 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
CA2839395A1 (en) 2011-07-12 2013-01-17 F. Hoffmann-La Roche Ag Aminomethyl quinolone compounds
US20150045305A1 (en) 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
EP2855472B1 (en) 2012-04-05 2016-09-14 Boehringer Ingelheim International GmbH Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
US9067894B1 (en) 2013-03-07 2015-06-30 Vanderbilt University Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014152317A2 (en) 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating gonorrhea infections using quinolone antibiotics
AR096022A1 (es) 2013-04-11 2015-12-02 Basf Se Compuestos de pirimidinio sustituido, útiles para combatir plagas de animales
WO2015019347A1 (en) 2013-08-08 2015-02-12 Yeda Research And Development Company Ltd. Girk as a therapeutic target of immune disorders and a marker of b cell subtypes
EP3088399A4 (en) 2013-12-26 2017-10-25 Kinki University Alkoxycarbonyl hemiacetal-type ester prodrug of pyridone carboxylic acid antibacterial drug
CN106573006A (zh) 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
EP3692991A1 (de) * 2015-06-09 2020-08-12 Bayer Pharma Aktiengesellschaft Positiv allosterische modulatoren des muskarinergen m2 rezeptors
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب

Also Published As

Publication number Publication date
KR20190066052A (ko) 2019-06-12
KR102540872B1 (ko) 2023-06-08
JOP20190086A1 (ar) 2019-04-18
EP3529251A1 (en) 2019-08-28
US20210284635A1 (en) 2021-09-16
RS63841B1 (sr) 2023-01-31
EP3529251B1 (en) 2022-10-05
RU2019115344A3 (es) 2021-02-20
PE20190735A1 (es) 2019-05-23
HRP20221516T1 (hr) 2023-02-17
US11530213B2 (en) 2022-12-20
CO2019003894A2 (es) 2019-04-30
BR112019007863A2 (pt) 2019-07-02
PH12019500849A1 (en) 2019-12-02
CN109843887A (zh) 2019-06-04
CU20190042A7 (es) 2019-11-04
US20190263803A1 (en) 2019-08-29
CL2019001023A1 (es) 2019-06-21
JP2019531326A (ja) 2019-10-31
SG11201902529WA (en) 2019-05-30
SA519401614B1 (ar) 2022-06-12
PT3529251T (pt) 2022-12-23
AU2017344489A1 (en) 2019-04-11
EP4141006A1 (en) 2023-03-01
CU24599B1 (es) 2022-06-06
DOP2019000100A (es) 2019-06-16
AU2017344489C1 (en) 2021-12-23
US20180111932A1 (en) 2018-04-26
TW201819377A (zh) 2018-06-01
FI3529251T3 (fi) 2023-01-13
IL266128B (en) 2021-06-30
CA3038624A1 (en) 2018-04-26
US10844055B2 (en) 2020-11-24
JP7030802B2 (ja) 2022-03-07
AU2017344489B2 (en) 2020-04-02
AU2020204341B2 (en) 2021-07-01
AU2020204341A1 (en) 2020-07-16
SI3529251T1 (sl) 2023-01-31
US10266531B2 (en) 2019-04-23
ECSP19026973A (es) 2019-04-30
UY37445A (es) 2018-05-31
CN109843887B (zh) 2022-05-10
IL266128A (en) 2019-06-30
TWI759343B (zh) 2022-04-01
PL3529251T3 (pl) 2023-01-30
HUE060882T2 (hu) 2023-04-28
LT3529251T (lt) 2023-01-10
ES2934234T3 (es) 2023-02-20
CR20190201A (es) 2019-06-04
WO2018073788A1 (en) 2018-04-26
RU2019115344A (ru) 2020-11-24

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
PH12016502246A1 (en) Carboxamide derivatives
EA201692298A1 (ru) Производные карбоксамидов
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
EA201991008A1 (ru) Новые производные нафтиридинона и их применение в лечении аритмии